RBC Capital raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $179 from $175 and keeps an Outperform rating on the shares. The company’s sole pipeline igniter, zanidatamab is on the path to becoming the next driver of the oncology portfolio over the long term with the upcoming PDUFA on January 29 in second-line HER2-positive biliary tract cancer, and the firm sees zani’s potential as a meaningful contributor to Jazz’s top line, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals Relocates Operations to New Premises
- Jazz Pharmaceuticals’ Zepzelca combination meets endpoints in lung cancer trial
- Jazz Pharmaceuticals presents updated Phase 2 data for zanidatamab
- Truist healthcare analyst holds an analyst/industry conference call
- Jazz Pharmaceuticals’ Epidiolex shows efficacy in epilepsy presentations